Findings

What do systematic reviews say?

266 questions · 269 findings · 41 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 85 · 31.6%GRADE not reported 3 · 1.1%Very low 62 · 23%Low 70 · 26%Moderate 46 · 17.1%High 3 · 1.1%

Surgery fee waiver with/without transport provision or reimbursement to improve access to cataract surgical services vs usual care

Prevalence of visual impairment due to cataract · people with vision impairment caused by cataract

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to improve access to cataract surgical services and their impact on equity in low‐ and middle‐income… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · people with AMD

Omega 3 fatty acids probably leads to higher loss of 3 or more lines of VA at 24 months compared with placebo (moderate certainty).

2 findings from 1 review

Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes only
RR 1.14
1 study · 236 participants
Moderate
Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes only
RR 1.25
1 study · 230 participants
Moderate

Omega‐3 vs placebo

Incidence of CNV at 24 months · people with AMD

Omega 3 fatty acids probably leads to higher incidence of CNV at 24 months compared with placebo (moderate certainty).

1 finding from 1 review

Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes only
RR 1.06
1 study · 224 participants
Moderate

Omega‐3 vs placebo

Incidence of CNV at 36 months · people with AMD

Omega 3 fatty acids probably leads to higher incidence of CNV at 36 months compared with placebo (moderate certainty).

1 finding from 1 review

Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes only
RR 1.12
1 study · 195 participants
Moderate

Omega‐3 vs placebo

Progression of AMD (dichotomous) · people with AMD

Omega 3 fatty acids showed no clear difference in progression of AMD over 5 years compared with placebo (high certainty).

1 finding from 1 review

Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes only
HR 0.96 [0.84, 1.1]
2 studies · 2343 participants
High

Omega‐3 vs placebo

Adverse effects · people with AMD

Omega 3 fatty acids leads to higher adverse effects compared with placebo (high certainty).

1 finding from 1 review

Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes only
RR 1.01
2 studies · 2343 participants
High